ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04398628|
Recruitment Status : Recruiting
First Posted : May 21, 2020
Last Update Posted : May 25, 2022
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness. In addition, results from well-controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.(1,2,3,4) In 2019 alone, the United States Food and Drug Administration (FDA) has issued approvals for twenty-four new therapies for congenital and acquired hematologic conditions.(5) In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.(6) With this explosion of potential new therapies on the horizon, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.(7)
The overarching objective of this longitudinal, observational study is to characterize the safety, effectiveness and practice of treatments for all people with congenital and acquired hematologic disorders in the US.
|Condition or disease|
|Hematologic Disorder Bleeding Disorder Connective Tissue Disorder Hemophilia Thrombosis Von Willebrand Diseases Thrombophilia Rare Bleeding Disorder Platelet Disorder|
This is a longitudinal, natural history observational cohort study being conducted at approximately 150 ATHN-affiliated sites. Participants will be followed for a minimum of 15 years. Harmonized data elements will be collected at time of enrollment, quarterly, ad hoc, and annually. Base data to be collected for all participants. Specific data will be collected for participants enrolled in cohort-specific Arms and Modules.
Each participant will be assigned in a single cohort: Hemophilia, Von Willebrand Disease, Congenital Platelet Disorder, Rare Bleeding Disorders, Bleeding not otherwise specified (NOS), Thrombosis/Thrombophilia, or Non-Neoplastic Hematologic Conditions. The cohort for which a participant qualifies will be determined by the site Investigator.
Study Arms and study Modules may be developed to provision disease and/or disease specific insights related to stakeholders, including but not limited to pharmaceutical companies, ATHN, and Hemophilia Treatment Centers (HTCs). Arms may branch off into product-specific data collection via Modules to be collected during the study, in conjunction with planned study assessments.
ATHN Transcends Principal Investigator: Michael Recht, MD, PhD, MBA American Thrombosis and Hemostasis Network
ATHN Transcends Co-Investigator: Lynn Malec, MD, MSc Versiti Blood Research Institute
Arm Principal Investigators:
Shannon Carpenter, MD, MS University of Missouri Kansas City School of Medicine Children's Mercy Hospital Courtney Thornburg, MD, MS University of California San Diego Rady Children's Hospital San Diego
Hemophilia Natural History Arm Tyler Buckner, MD, MSc Hemophilia and Thrombosis Center University of Colorado Anschutz Medical Campus Michael Recht, MD, PhD, MBA American Thrombosis and Hemostasis Network
Hemophilia Gene Therapy Outcomes Arm:
Janice M. Staber, MD Iowa Hemophilia and Thrombosis Center University of Iowa Stead Family Children's Hospital Ulrike M. Reiss, MD Hemophilia Treatment Center St. Jude's Children's Research Hospital
Severe VWD Natural History Arm:
Robert F. Sidonio, Jr., MD, MSc Aflac Cancer and Blood Disorders Center, Hemophilia of Georgia Center for Bleeding and Clotting Disorders Angela C. Weyand, MD C.S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor
|Study Type :||Observational|
|Estimated Enrollment :||3000 participants|
|Official Title:||ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders|
|Actual Study Start Date :||September 30, 2020|
|Estimated Primary Completion Date :||June 2035|
|Estimated Study Completion Date :||December 2035|
This cohort includes three Arms:
This Arm is for previously untreated patients (PUPs) with congenital hemophilia A or B. This is a longitudinal, observational, prospective and retrospective Arm of PUPs with moderate or severe congenital hemophilia. Participants will be followed to assess inhibitor development within 50 exposure days (ED).
Hemophilia Natural History Arm:
This Arm is investigating a natural history of the safety, effectiveness, and practice of treatment for people with hemophilia. It is a longitudinal, observational, prospective Arm for participants with acquired or congenital hemophilia A or B.
Hemophilia Gene Therapy Outcomes Arm:
This Arm is investigating the safety and effectiveness of gene therapy in people with hemophilia. It is a longitudinal, observational cohort Arm following participants prospectively and retrospective for 15 years after vector infusion.
Von Willebrand Disease
The Severe VWD Natural History Arm is investigating the natural history of the safety, effectiveness, and practice of treatment for people with severe von Willebrand disease (VWD). It is a longitudinal, observational cohort Arm following participants every 6 months for at least 2 years.
Congenital Platelet Disorders
No Arms or Modules at this time.
Rare Bleeding Disorders
No Arms or Modules at this time
No Arms or Modules at this time
No Arms or Modules at this time
Non-Neoplastic Hematologic Conditions
No Arms or Modules at this time
- To determine the safety of therapies used in the treatment of participants with congenital or acquired blood disorders, other non-neoplastic hematologic conditions and connective tissue disorders with bleeding tendency. [ Time Frame: 15 years ]
Safety will be measured by those events in the European Haemophilia Safety Surveillance (EUHASS).
- Allergic or other acute events
- Treatment-emergent side effects of therapy
- Transfusion transmitted infections
- Inhibitor development
- Cardiovascular events
- Neurological events
In addition to the modified EUHASS endpoints, the following events will be collected as adverse events of special interest (AESI):
A. The occurrence of thrombotic microangiopathies, injection site reactions and cases of potential drug-induced liver injury B. The development of anti-drug antibodies, to be measured and confirmed, if feasible C. Severe, unanticipated bleeding D. Hospitalizations
- To establish a platform to support study arms and modules for participants with bleeding, clotting, other non-neoplastic blood disorders, and connective tissue disorders with bleeding tendency [ Time Frame: 15 years ]For each Arm, a brief set of data elements of interests will be developed and reported for study participants.
- To describe medication dosing regimens in the above conditions [ Time Frame: 15 years ]
- Annualized bleeding rate (ABR), annualized spontaneous bleeding rate, annualized traumatic bleeding rate, annualized joint bleeding rate, and annualized non-joint bleeding rate
- Incidence of bleeding per surgical procedure describe the number and location of target joints upon study arm entry and to determine the incidence of target joint development and the proportion of target joints that resolve following Study Arm Enrollment
- To develop a biorepository for current and future research through the collection of biospecimens from every person enrolled on this protocol [ Time Frame: 15 years ]All participants will have the option of having specimens drawn (about 5mL each) at baseline to be stored in the ATHN Research Biorepository (ARB).
- To describe real-world effectiveness of therapies used in the above conditions by evaluating [ Time Frame: 15 years ]Health care utilization as measured by number and type of visits and hospitalizations per year
- To describe bleeding events, changes in overall bleeding, and annualized bleeding rate (ABR) as measured by individual bleeding components [ Time Frame: 15 years ]Calculated per ISTH Bleeding Assessment Tool (ISTH BAT)
- To describe effectiveness of therapies in the above conditions [ Time Frame: 15 years ]Patient reported outcomes (PROs) as measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Profile 29/25/Parent Proxy
- To describe treatment adherence in the above conditions [ Time Frame: 15 years ]Patient reported outcomes for treatment adherence as measured by Global Adherence Rating (GAR)
- To describe health related quality of life in the above conditions [ Time Frame: 15 years ]Patient reported outcomes including health related quality of life as measured by EQ-5D-5L. EQ-5D-5L is the correct term to use in print; it is a standardized measure of health developed by the EuroQol Group as a generic measure of health. There are five levels of perceived problems (Level 1 = no problem; Level 5 = unable to/extreme problems).
- To describe real-world effectiveness by evaluating [ Time Frame: 15 years ]Goal attainment as measured by GOAL-Hem for those participants that opt into this measurement. GOAL-HEM is the Goal Attainment Scaling for Life-Hemophilia scale. The scores are the sum of goal attainment x the relative goal weights transformed into a standard measure.
- To describe bleeding events and changes in overall bleeding [ Time Frame: 15 years ]The Pictorial Bleeding Assessment Chart (PBAC), for applicable diagnoses
Biospecimen Retention: Samples With DNA
All participants will have specimens drawn (about 5mL each) at baseline to be stored in the ATHN Research Biorepository (ARB).
Inhibitor testing is required for this study as follows:
- Baseline Visit (not required if no product has ever been given)
- At each Annual Visit (optional if no product given in interval from last test)
- At time of product switch
- At time of suspected inhibitor development
- At time of confirmatory test for previously elevated result
- At Study Exit
- Additional as per any modules
Genetic testing will be optional and provided by central labs, as funding allows, across all cohorts. Genetic testing will be performed once, for applicable participants.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04398628
|Contact: Carol Fedor, ND, RN, CCRC||800-360-2846 ext email@example.com|
|Contact: Carrie O'Neill||800-360-2846 ext firstname.lastname@example.org|
|United States, Arizona|
|Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital||Recruiting|
|Phoenix, Arizona, United States, 85016|
|Contact: Erica Sieber email@example.com|
|Principal Investigator: Christine Knoll, MD|
|United States, Indiana|
|Indiana Hemophilia and Thrombosis Center||Recruiting|
|Indianapolis, Indiana, United States, 46260|
|Contact: Nancy Hoard firstname.lastname@example.org|
|Principal Investigator: Amy Shapiro, MD|
|United States, Louisiana|
|Louisiana Center for Bleeding and Clotting Disorders, Tulane University||Recruiting|
|New Orleans, Louisiana, United States, 70112|
|Contact: Melody Benton email@example.com|
|Principal Investigator: Maissaa Janbain, MD|
|United States, Maine|
|Maine Hemophilia and Thrombosis Center||Recruiting|
|Scarborough, Maine, United States, 04074|
|Contact: Andrea Olas Andrea.firstname.lastname@example.org|
|Principal Investigator: Eric Larsen, MD|
|United States, Missouri|
|Children's Mercy Hospital - Kansas City||Recruiting|
|Kansas City, Missouri, United States, 64108|
|Contact: Lois Hester email@example.com|
|Principal Investigator: Shannon Carpenter, MD|
|The John Bouhasin Center for Children with Bleeding Disorders||Recruiting|
|Saint Louis, Missouri, United States, 63104|
|Contact: Gina Martin firstname.lastname@example.org|
|Principal Investigator: John Puetz, MD|
|United States, Nevada|
|Hemostasis and Thrombosis Center of Nevada||Recruiting|
|Reno, Nevada, United States, 89509|
|Contact: Lisa Cervantes email@example.com|
|Principal Investigator: Daisy Cortes, MD|
|United States, New York|
|American Thrombosis and Hemostasis Network||Recruiting|
|Rochester, New York, United States, 14626|
|Contact: Carrie O'Neill firstname.lastname@example.org|
|United States, Pennsylvania|
|Children's Hospital of Philadelphia||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Rochelle Jordan email@example.com|
|Principal Investigator: Leslie Raffini, MD|
|United States, Texas|
|North Texas Hemophilia and Thrombosis Program - Pediatric Program / Center for Cancer & Blood Disorders||Recruiting|
|Dallas, Texas, United States, 75235|
|Contact: Anna Winborn ANNA.WINBORN@childrens.com|
|Principal Investigator: Ayeshia Zia, MD|
|Principal Investigator:||Michael Recht, MD, PhD, MBA||American Thrombosis and Hemostasis Network|
|Principal Investigator:||Lynn Malec, MD, MSc||Versiti Blood Research Institute|